ARID1A and neoplasm: A second benefit of targeting ARID1A is the recent demonstration that inactivation of certain SWI/SNF chromatin remodelling complex subunits (i.e. ARID1A and PBRM1) renders tumours more likely to respond to ICIs32,46.